Breakthrough bacteraemia with a susceptible Enterococcus faecalis during tigecycline monotherapy

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 2, 2009, Pages 370-374

  Parsonage, Mirella ^a   Shah, Shital ^a   Moss, Peter ^a   Thaker, Hiten ^a   Meigh, Rolf ^a   Balaji, Ariyur ^a   Elston, James ^a   Barlow, Gavin ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

E. faecalis; Endocarditis; Failure

Indexed keywords

AMOXICILLIN; C REACTIVE PROTEIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; PENICILLIN G; RIFAMPICIN; STEROID; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACKACHE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; HEART FAILURE; HUMAN; LETTER; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RHEUMATIC POLYMYALGIA; RIGOR; SKIN ALLERGY; SKIN INFECTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSTHORACIC ECHOCARDIOGRAPHY; VEGETATION;

EID: 77950214455     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp455     Document Type: Letter

References (18)

1. Oliva ME, Rekha A, Yellin A et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005; 5: 88.
2. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycinaztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
3. Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 329-38.
4. Curcio D. Tigecycline for treating bloodstream infections: a critical analysis of the available evidence. Diagn Microbiol Infect Dis 2008; 61: 358-9.
5. Tygacil: European Public Assessment Report. EMEA/H/C/644 (2006). www.emea.europa.eu/humandocs/PDFs/EPAR/tygacil/H-644-en1.pdf (8 November 2009, date last accessed).
6. Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007; 2: 343-4.
7. Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother 2009; 43: 2108-12.
8. Lefort A, Lafaurie M, Massias L et al. Activity and diffusion of tigecycline (GAR 936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003; 47: 216-22.
9. Florescu I, Beuran M, Dimov R et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62 Suppl 1: i17-28.
10. Cunha BA. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant Gram-negative bacteraemias. J Chemother 2007; 19: 232-3.
11. Schafer JJ, Goff DA, Stevenson KB et al. Early experience with tigecycline for ventilator-associated pneumonia and bacteraemia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007; 27: 980-7.
12. Anthony K, Fishman N, Linkin D et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567-70.
13. Gallagher JC, Rouse HM. Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 2008; 42: 1188-94.
14. Vasilev K, Reshedko G, Orasan R et al. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62 Suppl 1: i29-40.
15. Cobo J, Morosini MI, Pintado V et al. Use of tigecycline for the treatment of prolonged bacteraemia due to a multiresistant VIM-1 and SHV-12 b-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 2008; 61: 319-22.
16. Knueppel RC, Rahimian J. Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B. Clin Infect Dis 2007; 45: 136-8.
17. Souli M, Kontopidou M, Papadomichelakis E. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-b-lactamase in a Greek university hospital. Clin Infect Dis 2008; 46: 847-54.
18. Rolston K, Raad I, Hachem R et al. Tigecycline use in cancer patients with serious infections. A report on 110 cases from a single institution. Medicine 2009; 88: 211-20.